chronic myelomonocytic leukemia
GPTKB entity
Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:myelodysplastic_syndromes
|
| gptkbp:affects |
blood cells
|
| gptkbp:clinical_trial |
ongoing research
thrombocytopenia leukocytosis hepatomegaly splenomegaly monocytosis |
| gptkbp:current_use |
gptkb:myelodysplastic_syndromes
gptkb:healthcare_organization |
| gptkbp:end_of_life |
depends on various factors
|
| gptkbp:genetic_diversity |
recommended
ASX L1 TE T2 SRS F2 |
| https://www.w3.org/2000/01/rdf-schema#label |
chronic myelomonocytic leukemia
|
| gptkbp:is_a_route_for |
abnormal proliferation of monocytes
|
| gptkbp:is_monitored_by |
regular blood tests
|
| gptkbp:is_popular_in |
rare
|
| gptkbp:occurs_in |
approximately 1 in 100,000
|
| gptkbp:population |
more common in males
more common in older adults |
| gptkbp:premiered_on |
over 60
|
| gptkbp:research_focus |
new therapies
|
| gptkbp:risk_factor |
age
chemical exposure exposure to radiation |
| gptkbp:scholarships |
support groups
|
| gptkbp:scientific_classification |
gptkb:myelodysplastic_syndromes
myeloproliferative neoplasms |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea hair loss infection risk |
| gptkbp:social_responsibility |
variable
flow cytometry cytogenetic analysis bone marrow biopsy dysplastic changes in blood cells persistent monocytosis |
| gptkbp:symptoms |
gptkb:fandom
fatigue weight loss bruising fever supportive care bleeding night sweats infections bone pain enlarged spleen pallor |
| gptkbp:treatment |
gptkb:vaccine
variable clinical trials chemotherapy targeted therapy remission stem cell transplant hypomethylating agents |